Mostrar el registro sencillo del ítem
dc.contributor.author
Hirschler, Valeria
dc.contributor.author
Meroño, Tomás
dc.contributor.author
Maccallini, Gustavo
dc.contributor.author
Gomez Rosso, Leonardo Adrián
dc.contributor.author
Aranda, Claudio
dc.contributor.author
Brites, Fernando Daniel
dc.date.available
2020-09-07T20:55:22Z
dc.date.issued
2011-04
dc.identifier.citation
Hirschler, Valeria; Meroño, Tomás; Maccallini, Gustavo; Gomez Rosso, Leonardo Adrián; Aranda, Claudio; et al.; Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys; Bentham Science Publishers; Cardiovascular and Hematological Agents in Medicinal Chemistry; 9; 2; 4-2011; 78-83
dc.identifier.issn
1871-5257
dc.identifier.uri
http://hdl.handle.net/11336/113428
dc.description.abstract
Abstract: Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been proposed as a biomarker of risk of cardiovascular disease (CVD). Objective: To determine the association between Lp-PLA2 activity and BMI, insulin-resistance, components of the metabolic syndrome (MS), and lifestyle behaviors in healthy adolescent boys. Methods: Data were collected cross-sectionally from 164 adolescents from an amateur rugby club. BMI, blood pressure (BP), Tanner stages, glucose, insulin, lipids, and Lp-PLA2 activity were measured. Questionnaires for lifestyle behaviors were completed. Results: Approximately 26% of the adolescents were obese and 23% overweight. There was a univariate association between Lp-PLA2 and BMI (r=0.16;p=0.042), triglycerides (r=0.26;p=0.001), LDL-C (r=0.46;p<0.001), apo B (r=0.55;p<0.001), whereas waist circumference, BP, glucose, HOMA-IR, and HDL-C were not correlated. None of the lifestyle behaviors were significantly correlated with Lp-PLA2. In order to analyze Lp-PLA2 association with known CVD risk conditions, adolescents were categorized according to overweight/obesity and to the presence of metabolic syndrome. Conversely, as it was for LDL-C and apo B concentration, Lp-PLA2 activity was not higher in adolescents with obesity. Multiple regression analysis showed that apo B was significantly associated with Lp-PLA2 adjusted for age, BMI, triglyc-erides and LDL-C (R2=0.32). Conclusion: Lp-PLA2 activity was only associated with apo B adjusted for several confounding variables, suggesting that its clinical utility to identify individuals at risk for CVD does not surpass LDL-C and apo B in healthy adolescents. As plaque morphology may change with age, associations of Lp-PLA2 with CVD may likewise vary with age.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Bentham Science Publishers
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
ADOLESCENTS
dc.subject
APO B
dc.subject
ATHEROSCLEROSIS
dc.subject
CARDIOVASCULAR DISEASE
dc.subject
CETP
dc.subject
CHILDREN
dc.subject
INSULIN RESISTANCE
dc.subject
LIPOPROTEIN PROFILE
dc.subject
LP-PLA2
dc.subject
METABOLIC SYNDROME
dc.subject
OBESITY
dc.subject.classification
Pediatría
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-09-03T16:59:07Z
dc.identifier.eissn
1875-6182
dc.journal.volume
9
dc.journal.number
2
dc.journal.pagination
78-83
dc.journal.pais
Países Bajos
dc.journal.ciudad
Amsterdam
dc.description.fil
Fil: Hirschler, Valeria. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
dc.description.fil
Fil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Maccallini, Gustavo. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
dc.description.fil
Fil: Gomez Rosso, Leonardo Adrián. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Aranda, Claudio. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
dc.description.fil
Fil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
dc.journal.title
Cardiovascular and Hematological Agents in Medicinal Chemistry
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.2174/187152511796196542
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/74546/article
Archivos asociados